Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | DUT | P33316 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25949223 | 0.89 | HDAC3 (0.45) | HDAC3HDAC1HDAC2LMNA | |
| SCHEMBL14288491 | 0.87 | KCNN4 (0.63) | KCNN4KIF11HDAC3HDAC1HDAC2 | |
| SCHEMBL9439820 | 0.86 | KIF11 (0.47) | KCNN4KIF11KCNH2DRD2DRD4 | |
| SCHEMBL25868983 | 0.86 | HTT (0.47) | KCNN4KIF11KCNH2DRD2DRD4 | |
| SCHEMBL5391076 | 0.86 | KIF11 (0.61) | KCNN4KIF11KCNH2DRD2DRD4 | |
| SCHEMBL4363002 | 0.84 | KIF11 (0.49) | KCNN4KIF11KCNH2DRD2DRD4 | |
| SCHEMBL12225852 | 0.84 | KIF11 (0.49) | KCNN4KIF11KCNH2DRD2DRD4 | |
| SCHEMBL8040236 | 0.84 | KIF11 (0.44) | KCNN4KIF11KCNH2DRD2DRD4 | |
| SCHEMBL6302955 | 0.84 | KIF11 (0.45) | KCNN4KIF11KCNH2DRD2DRD4 | |
| SCHEMBL8053146 | 0.84 | KIF11 (0.45) | KCNN4KIF11KCNH2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3838913-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREFOR | MabPlex International Co., Ltd. (CN) | 2021-06-23 | — | — | EP | disclosed |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | SNRPE, PHAX, SNRPA | KCNN4 4732/4885KIF11 758/4885KCNH2 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.